The first BH3 mimetics, ABT-737 and ABT-263 (Navitoclax), inhibit BCL-2, BCL-XL, and BCL-w10,11, and were followed by more selective inhibitors, such as the BCL-2-specific Venetoclax (ABT-199), recently approved for treatment of chemorefractory chronic lymphocytic leukemia12,13, in addition to newly diagnosed acute myeloid leukemia, in combination with hypermethylating agents, such as azacytidine and decytabine14. The gene discussed is BCL2; the disease is acute myeloid leukemia.